


(51) International Patent Classification:
C12N 5/10 (2006.01)(21) International Application Number:
PCT/IB2018/000510(22) International Filing Date:
05 April 2018 (05.04.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/483,298 07 April 2017 (07.04.2017) US(71) Applicant: UTI LIMITED PARTNERSHIP [CA/CA];
3553 31st Street NW, Suite 130, Calgary, AB T2L 2K7
(CA).(72) Inventor: SANTAMARIA, Pedro; 6923 Christie Estates
Blvd. SW, Calgary, AB T3H 2S3 (CA).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).**Published:**— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(54) Title: ASSAY TO MEASURE THE POTENCY OF RECEPTOR-LIGAND INTERACTIONS IN NANOMEDICINES

**FIG. 1H**(57) **Abstract:** Described herein, is an isolated cell comprising a recombinant T cell receptor (TCR) and a TCR- pathway-dependent reporter, wherein the recombinant T cell receptor is specific for a disease- relevant antigen bound to an MHC molecule. Also described are methods of use for the isolated cell as an assay to determine the function or potency of a peptide-major histocompatibility complex (pMHC) coupled to a nanoparticle (pMHC-NP) that can be used as a medicine for treating an autoimmune disease or cancer.